Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Semin Arthritis Rheum. 2016 Aug 24;46(4):423–429. doi: 10.1016/j.semarthrit.2016.08.011

Figure 3.

Figure 3

Comparison of use of TNFα inhibitors and traditional DMARDs between cases and controls.

*TNFα inhibitors including Adalimumab, Certolizumab, Etanercept, Infliximab, and Golimumab

±Traditional DMARDS including Azathioprine, Hydroxychloroquine, Leflunomide, and Methotrexate

Note: Above each bar is listed the percent of patients taking that class of drug who have RA, whether in the case or control group; this should be contrasted to 8%, the percent of patients with RA in the full sample of cases and controls. For example, 93% of patients taking a TNFα inhibitor who did not get infections had RA, and 69% of those in the case group who were taking this class of drug had RA.